Treatment of neuro-Behçet’s disease: an update

References

• Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet’s disease: a review. Neurologist11, 80–89 (2005).
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Serdaroglu P, Tasci B; the Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain122, 2171–2182 (1999).
   PubMed Web of Science ®Google Scholar
• Davatchi F. Behçet’s disease: global perspective. Indian J. Rheumatol.2, 65–71 (2007).
   Google Scholar
• Scolding NJ, Joseph FG. Neuro-Behçet’s disease in Caucasians: a study of 22 patients. Eur. J. Neurol.14(2), 174–180 (2007).
   PubMedGoogle Scholar
• Suda A, Takeno M, Ideguchi H et al. Neurological manifestations in Japanese patients with Behçet’s disease: a retrospective analysis in Japan (I 8). Presented at: 13th International Congress on Behçet’s Disease. Pörtschach/Klagenfurt, Austria, 24–27 May 2008.
   Google Scholar
• Kurtuncu M, Tuzen E, Mutlu M, Pehlivan M, Serdaroglu P, Akman Demir G. Clinical patterns and course of neuro-Behçet’s disease. Analysis of 354 patients comparing cases presented before and after 1990 (I 7). Presented at: 13th International Congress on Behçet’s Disease. Pörtschach/Klagenfurt, Austria, 24–27 May 2008.
   Google Scholar
• Borhani Haghighi A, Samangooie S, Ashjazadeh N et al. Neurological manifestations of Behçet’s disease. Saudi Med. J.27(10), 1542–1546 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behçet’s disease: a prospective study from Iraq. J. Neurol. Neurosurg. Psychiatry74(5), 608–613 (2003)
   PubMed Web of Science ®Google Scholar
• Serdaroglu P. Behçet’s disease and the nervous system. J. Neurol.245(4), 197–205 (1998).
   PubMed Web of Science ®Google Scholar
• Aykutlu E, Baykan B, Serdaroglu P, Gökyigit A, Akman-Demir G. Epileptic seizures in Behçet disease. Epilepsia43(8), 832–835 (2002)
   PubMed Web of Science ®Google Scholar
• Bogdanova D, Milanov I, Georgiev D. Parkinsonian syndrome as a neurological manifestation of Behçet’s disease. Can. J. Neurol. Sci.25, 82–85(1998).
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Aflaki E, Ketabchi L. The prevalence and characteristics of different types of headache in patients with Behçet’s disease. Headache48, 424–429 (2008)
   PubMed Web of Science ®Google Scholar
• Saip S, Siva A, Altintas A et al. Headache in Behçet’s syndrome. Headache45, 911–919 (2005)
   PubMed Web of Science ®Google Scholar
• Calikoglu E, Onder M, Cosar B, Candansayar S. Depression, anxiety levels and general psychological profile in Behçet’s disease. Dermatology203(3), 238–240 (2001).
   PubMed Web of Science ®Google Scholar
• Davis LE, Hodgin VG, Kornfeld M. Recurrent meningoencephalitis with recovery from Behçet’s disease. West. J. Med.145, 238–239 (1986).
   PubMedGoogle Scholar
• Appenzeller S, de Castro R, de Queiroz LS et al. Brain tumor-like lesion in Behçet disease. Rheumatol. Int.26, 577–580 (2006).
   PubMed Web of Science ®Google Scholar
• Schmolck H. Large thalamic mass due to neuro-Behçet disease. Neurology965, 436 (2005).
   Google Scholar
• Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G. Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur. J. Neurol.14(7), 729–737 (2007).
   PubMed Web of Science ®Google Scholar
• Wechsler B, Vidailhet M, Piette JC et al. Cerebral venous thrombosis in Behcet’s disease: clinical study and long-term follow-up of 25 cases. Neurology42, 614–618 (1992).
   PubMed Web of Science ®Google Scholar
• Krespi Y, Akman-Demir G, Poyraz M et al. Cerebral vasculitis and ischaemic stroke in Behçet’s disease: report of one case and review of the literature. Eur. J. Neurol.8(6), 719–722 (2001).
   PubMed Web of Science ®Google Scholar
• Borahni Haghighi A, Sharifzad HR, Matin S, Rezaee S. The pathological presentations of neuro-Behçet disease: a case report and review of the literature. Neurologist13(4), 209–214 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshimura J, Toyama M, Sekihara Y et al. Neuro-Behcet disease mimicking a thalamic tumor. No Shinkei Geka29, 527–531 (2001).
   PubMedGoogle Scholar
• Matsuo K, Yamada K, Nakajima K et al. Neuro-Behçet disease mimicking brain tumor. Am. J. Neuroradiol.26, 650–653 (2005).
   PubMed Web of Science ®Google Scholar
• Arai T, Mizukami K, Sasaki M et al. Clinicopathological study on a case of neuro-Behçet disease: in special reference to MRI, SPECT and neuropathological findings. Jpn. J. Psychiatry Neurol.48, 77–84 (1994).
   PubMedGoogle Scholar
• Hadfield MG, Aydin F, Lippman HR et al. Neuro-Behçet disease. Clin. Neuropathol.15, 249–255 (1996).
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A. Comment on “Histopathology of central nervous system lesions in Behçet’s disease”. J. Neurol. Sci.270(1–2), 211 (2008).
   PubMedGoogle Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet335, 1078–1080 (1990).
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Aflaki E, Haghshenas S, Savagheb S, Davoudi S. Psychometric evaluation of patients with Behçet’s disease. Iranian J. Med. Sci.32(2), 110–113 (2008).
   Google Scholar
• Kang DW, Chu K, Cho JY et al. Diffusion weighted magnetic resonance imaging in neuro-Behçet’s disease. J. Neurol. Neurosurg. Psychiatry70, 412–413 (2001).
   PubMed Web of Science ®Google Scholar
• Nussel F, Wegmuller H, Laseyras F et al. Neuro-Behçet’s: acute and sequential aspects by MRI and MRS. Eur. Neurol.31, 399–402 (1991).
   PubMed Web of Science ®Google Scholar
• Kocek N, Islak C, Siva A et al. CNS involvement in Neuro-Behçet syndrome: an MR study. Am. J. Neuroradol.20, 1015–1024 (1999).
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Bahar S, Coban O, Tasci B, Serdaroglu P. Cranial MRI in Behçet’s disease: 134 examinations of 98 patients. Neuroradiology45(12), 851–859 (2003).
   PubMed Web of Science ®Google Scholar
• Bohlega S, Al–Kawi MZ, El–Ramahi K. Factors hampering prognosis in neuro-Behçet’s disease. Neurology48(Suppl. 3), A98 (1997)
   Web of Science ®Google Scholar
• Siva A, Kantarcy O, Saip S. Hamuryudan V, Altyntas A, Yazici H. Neuro-Behçet syndrome: prognostic factors and survival. J. Neurol.245, 362 (1998).
   Google Scholar
• Hatemi G, Silman A, Bang D et al. EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis.67(12), 1656–1662 (2008).
   PubMed Web of Science ®Google Scholar
• Davatchi F. New and innovative therapies for Behçet’s disease . APLAR J. Rheumatol.7, 141–145 (2004).
   Google Scholar
• Mat C, Yurdakul S, Uysal S et al. A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford)45(3), 348–352 (2006).
   PubMed Web of Science ®Google Scholar
• de Souza-Ramalho P, D’Almeida MF, Freitas JP, Pinto J. Behçet’s disease in Portugal. Acta Med. Port.4(2), 79–82 (1991).
   PubMedGoogle Scholar
• Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behçet’s syndrome. N. Engl. J. Med.322(5), 326–328 (1990).
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N et al. Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum.40(4), 769–774 (1997).
   PubMed Web of Science ®Google Scholar
• Sies C, Florkowski C, George P et al.Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. NZ Med. J.118(1210), U1324 (2005).
   Google Scholar
• Garrick V, Atwal P, Barclay AR, McGrogan P, Russell RK. Successful implementation of a nurse-led teaching programme to administer methotrexate in the community setting to children with Crohn’s disease. Aliment Pharmacol. Ther. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Chikura B, Sathi N, Lane S, Dawson JK. Variation of immunological response in methotrexate-induced pneumonitis. Rheumatology (Oxford)47(11), 1647–1650 (2008).
   PubMed Web of Science ®Google Scholar
• Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet’s disease. J. Neurol. Sci.159(2), 181–185 (1998).
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behçet’s disease. A follow-up study for 4 years. Adv. Exp. Med. Biol.528, 575–578 (2003).
   PubMed Web of Science ®Google Scholar
• Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C. Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr. Radiol.36(3), 205–212 (2006).
   PubMed Web of Science ®Google Scholar
• Saenz A, Ausejo M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behçet’s syndrome. Cochrane Database Syst. Rev.2, CD001084 (2000).
   Google Scholar
• Hamza M, Meddeb S, Mili I, Ouertani A. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Behçet’s disease. Preliminary results with the use of new criteria of evaluation]. Ann. Med. Interne (Paris)143(7), 438–441 (1992).
   PubMedGoogle Scholar
• Du LT, Fain O, Wechsler B, Cochereau I et al. [Value of ‘bolus’ cyclophosphamide injections in Behçet’s disease. Experience of 17 cases]. Presse Med.19(9), 1355–1358 (1990).
   PubMed Web of Science ®Google Scholar
• Boura P, Tselios K, Kamali S, Skendros P, Sarantopoulos A, Topouzis F. Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behçet disease (ABD). Neurol. Sci.27(6), 432–435 (2006).
   PubMed Web of Science ®Google Scholar
• Siva A, Fresko II. Behçet’s disease. Curr. Treat. Options Neurol.2(5), 435–448 (2000).
   PubMedGoogle Scholar
• Watanabe T, Shimoji S, Sugiyama Y, Tsukamoto T, Yamamoto T. [Pulse-dose cyclophosphamide therapy for steroid-refractory autoimmune neurological diseases]. Rinsho Shinkeigaku35(6), 611–616 (1995).
   PubMedGoogle Scholar
• Melillo N, Sangle S, Stanford MR, Andrews TC, D’Cruz DP. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet’s disease. Clin Rheumatol.26(8), 1365–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Glimelius B et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkins lymphoma. J. Natl Cancer Inst.87, 524–530 (1995).
   PubMed Web of Science ®Google Scholar
• Mateos-Colino A, Gonzalez-Gay MA, Cereijo MJ, Santiago J, Rabuñal R, Brañas F. [Neuro-Behçet: a follow-up of 4 cases treated with chlorambucil]. An. Med. Interna12(12), 600–602 (1995).
   PubMedGoogle Scholar
• O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephaliltis of Behçet’s disease. Am. J. Med.76, 75–84 (1984).
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon a in Behçet disease: review of the literature. Semin. Arthritis Rheum.33, 320–335 (2004).
   PubMed Web of Science ®Google Scholar
• Calguneri M, Ozturk MA, Ertenli I et al. Effects of interferon-α treatment on the clinical course of refractory Behçet’s disease: an open study. Ann. Rheum. Dis.62, 492–493 (2003).
   PubMed Web of Science ®Google Scholar
• Kötter I, Vonthein R, Zierhut M et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin. Arthritis Rheum.33(5), 311–319 (2004).
   PubMed Web of Science ®Google Scholar
• Nichols JC, Ince A, Akduman L et al. Interferon-α 2a treatment of neuro-Behcet’s disease. J. Neuroophthalmol.21, 109–111 (2001).
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, Zierhut M, Batra M, Koetter I. Interferon-α – a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement. Rheumatology (Oxford)47(7), 1051–1053 (2008)
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, May T. Pathogenesis of Adamantiades-Behçet’s disease. Med. Microbiol. Immunol.192, 149–155 (2003).
   PubMed Web of Science ®Google Scholar
• Reimold AM. TNF a as therapeutic target: new drugs, more applications. Curr. Drug Targets Inflamm. Allergy.1(4), 377–392 (2002).
   PubMedGoogle Scholar
• Licata G, Pinto A, Tuttolomondo A et al. Anti-tumour necrosis factor α monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet’s syndrome. Ann. Rheum. Dis.62(3), 280–281 (2003).
   PubMedGoogle Scholar
• Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet’s disease with infliximab. J. Rheumatol.32, 181–183 (2005).
   PubMed Web of Science ®Google Scholar
• Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF-α blockade in cyclophosphamide resistant neuro-Behçet disease. J. Neurol. Neurosurg. Psychiatry76(12), 1733–1735 (2005).
   PubMed Web of Science ®Google Scholar
• Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behçet’s disease is successfully treated with etanercept: further evidence for the value of TNF-α blockade. Clin. Neurol. Neurosurg.109(3), 279–281 (2007).
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Aratake K, Kawakami A et al.Successful treatment of refractory neuro-Behçet’s disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann. Rheum. Dis.66, 136–137 (2007).
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Safari A. Anti-tumor necrotic factor antibody for treatment of neuro-Behcet’s disease, a case report. Clin. Neurol. Neurosurg.110(3), 315–316 (2008).
   PubMed Web of Science ®Google Scholar
• van Laar JAM, Missotten T, van Daele PLA, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet’s disease? Ann. Rheum. Dis.66, 565–566 (2007).
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Padula A et al. Infliximab for the treatment of neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum.59(2), 285–290 (2008).
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet’s syndrome. J. Neurol. Sci.272(1–2), 99–105 (2008).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Alpsoy E et al. Anti-TNF therapy in the management of Behçet’s disease – review and basis for recommendations. Rheumatology (Oxford)46(5), 736–741 (2007).
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Mat C, Saip S et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.128(6), 443–450 (1998).
   PubMed Web of Science ®Google Scholar
• Ranselaar CG, Boone RM, Kluin-Nelemans HC. Thalidomide in the treatment of neuro-Behçet’s syndrome. Br. J. Dermatol.115, 367–370 (1986).
   PubMed Web of Science ®Google Scholar
• Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J. Dermatol.29(5), 267–279 (2002).
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tüzün Y et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum.44(11), 2686–2692 (2001).
   PubMed Web of Science ®Google Scholar
• Cobellis L, Pecori E, Rigatti F et al.Therapeutic alternatives in Behçet’s syndrome. Clin. Exp. Obstet. Gynecol.34(3), 151–153 (2007).
   PubMed Web of Science ®Google Scholar
• Davatchi F. Treatment of ocular manifestations of Behçet’s disease. Adv. Exp. Med. Biol.528, 487–491 (2003).
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Batra M et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications – results of a retrospective analysis of 117 cases. Clin. Rheumatol.25(4), 482–486 (2006).
   PubMed Web of Science ®Google Scholar
• Meusser S, Eger G, Anders M, Burkhardt H, Kalden JR. [Manifestation of neuro-Behçet disease in cyclosporin A therapy]. Z. Rheumatol.56(1), 31–39 (1997).
   PubMed Web of Science ®Google Scholar
• Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous systems symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology106, 586–589 (1999).
   PubMed Web of Science ®Google Scholar
• Inaba G. Behçet’s disease. In: Handbook of Clinical Neurology. Vinken PJ, Bruyn GW, KlawansHL(Eds). Elsevier Science, Amsterdam, The Netherlands (1989).
   Google Scholar
• Ishioka M, Ohno S, Nakamura S et al. FK506 treatment of noninfectious uveitis. Am. J. Ophthalmol.118, 723–729 (1994).
   PubMed Web of Science ®Google Scholar
• Igarashi I, Ishigatsubo Y, Ohno S et al. Central nervous system toxicity related to FK506 in patients with Behçet’s disease. Ann. Rheum. Dis.53, 350–351 (1994).
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford)42(12), 1539–1544 (2003).
   PubMed Web of Science ®Google Scholar
• Hirohata S, Isshi K, Oguchi H et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet’s syndrome. Clin. Immunol. Immunopathol.82(1), 12–17 (1997).
   PubMedGoogle Scholar
• Borhani Haghighi A, Safari A. Tocilizumab may be a potential addition to our weapons against Q2 neuro-Behçet’s disease. Med. Hypotheses71(1), 156–157 (2008).
   PubMed Web of Science ®Google Scholar
• Stanford M, Whittall T, Bergmeier LA et al. Oral tolerization with peptide 336–351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behçet’s disease. Clin. Exp. Immunol.137, 201–208 (2004).
   PubMed Web of Science ®Google Scholar
• De Cata A, Intiso D, Bernal M et al.. Prolonged remission of neuro-Behçet disease following autologous transplantation. Int. J. Immunopathol. Pharmacol.20(1), 91–96 (2007).
   PubMed Web of Science ®Google Scholar
• Siva A. Vasculitis of the nervous system. J. Neurol.248, 451–468 (2001).
   PubMed Web of Science ®Google Scholar
• Bank I, Weart C. Dural sinus thrombosis in Behçet’s disease. Arthritis Rheum.27, 816–818 (1984).
   PubMedGoogle Scholar
• Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behçet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin. Rheumatol.27(2), 201–205 (2008).
   PubMed Web of Science ®Google Scholar
• Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat. Clin. Pract. Rheumatol.3(3), 148–155 (2007).
   PubMedGoogle Scholar
• Alpagut U, Ugurlucan M, Dayioglu E. Major arterial involvement and review of Behçet’s disease. Ann. Vasc. Surg.21(2), 232–239 (2007).
   PubMed Web of Science ®Google Scholar
• Barlas S. Behçet’s disease. An insight from a vascular surgeon’s point of view. Acta Chir. Belg.99(6), 274–281 (1999).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum.52(8), 2513–2518 (2005).
   PubMed Web of Science ®Google Scholar
• Gul A. Standard and novel therapeutic approaches to Behçet’s disease. Drugs67(14), 2013–2022 (2007).
   PubMed Web of Science ®Google Scholar